Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Trial victory for Magnolia Medical in patent infringement litigation
We secured a unanimous jury verdict against Magnolia’s sole competitor in the market for initial specimen diversion devices
PegBio HK$300 million placement of shares
We advised PegBio on the placement of new shares
GSK strategic collaboration with CAMP4 Therapeutics
We advised GSK on the transaction
Kodiak Sciences $184 million stock offering
We advised the underwriters on the offering
Zoetis $2 billion convertible senior notes offering
We advised the representatives of the initial purchasers on the offering
Tenaya Therapeutics $60 million units offering
We advised the joint book-running managers and representatives of the several underwriters
LifeScan emerges from chapter 11
We advised an ad hoc group of secured lenders in connection with LifeScan’s chapter 11 proceedings
Sevita $1.275 billion notes offering
We advised the representative of the initial purchasers on the offering
Terns Pharmaceuticals $747.5 million stock offering
We advised the underwriters on the public offering
Biocytogen RMB1.27 billion Shanghai IPO
We advised Biocytogen on its IPO and SSE listing